Abstract | BACKGROUND: METHOD: RESULTS: Eleven (42%) of the patients with PTSD experienced yohimbine-induced panic attacks and had significantly greater increases compared with controls in anxiety, panic, and PTSD symptoms, but not in cardiovascular measurements. Eight patients (31%) with PTSD experienced m-CPP-induced panic attacks and had significantly greater increases compared with controls in anxiety, panic, and PTSD symptoms, and in standing diastolic blood pressure. Yohimbine-induced panic attacks tended to occur in different patients from m-CPP-induced panic attacks. CONCLUSION: These data suggest the presence of 2 neurobiological subgroups of patients with PTSD, one with a sensitized noradrenergic system, and the other with a sensitized serotonergic system.
|
Authors | S M Southwick, J H Krystal, J D Bremner, C A Morgan 3rd, A L Nicolaou, L M Nagy, D R Johnson, G R Heninger, D S Charney |
Journal | Archives of general psychiatry
(Arch Gen Psychiatry)
Vol. 54
Issue 8
Pg. 749-58
(Aug 1997)
ISSN: 0003-990X [Print] United States |
PMID | 9283511
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Piperazines
- Yohimbine
- Serotonin
- 1-(3-chlorophenyl)piperazine
- Norepinephrine
|
Topics |
- Adult
- Double-Blind Method
- Humans
- Hypertension
(chemically induced)
- Male
- Norepinephrine
(physiology)
- Panic Disorder
(chemically induced)
- Piperazines
(pharmacology)
- Serotonin
(physiology)
- Stress Disorders, Post-Traumatic
(physiopathology)
- Yohimbine
(pharmacology)
|